As of one year ago, UnitedHealth Group (UNH) was experiencing a severe and volatile downward correction, trading at approximately $300 to $312 per share. Down from its all-time closing high of $603.20 in November, 2024.
The CEO, Andrew Witty, had suddenly stepped down, the company pulled its forecasts, and a federal probe hung over the business, sending its share price toward levels unseen since 2020.
Now, the same analysts who downgraded the stock last year are racing to raise their numbers.
On Monday, June 8, JPMorgan raised its target sharply, and another major firm matched it within the hour, sending the stock to a fresh 52-week high.
JPMorgan lifts its UnitedHealth price target to a Street-leading number
JPMorgan raised its price target on UnitedHealth Group (UNH) to $466 from $420 and kept an “overweight” rating, MarketBeat reported.
That sits at the top of the recent wave of bullish calls, pointing to roughly 14% above this week’s price.
An “overweight” rating is the bank’s way of saying it expects the stock to beat its industry peers over the next year.
Shortly after, Mizuho lifted its own target to $460 from $440 and kept an “outperform” rating, TipRanks reported.
More Healthcare Stocks:
- Warren Buffett’s Berkshire sells rebounding healthcare stock
- Mark Cuban goes in hard on the American healthcare system
- Microsoft and Copilot just hit a jackpot in healthcare
Mizuho framed the bigger picture clearly, telling clients that the managed care sector is entering a calmer policy stretch, with surprise rule changes from Washington easing off after three rough years.
This matters because policy shocks, not weak demand, drove most of the pain in the healthcare stocks category.
Why the UnitedHealth turnaround looks good right now
To understand the enthusiasm, remember how bad 2025 got.
CEO Andrew Witty stepped down in May 2025, CNN reported, the board brought back former chief Stephen Hemsley, and the company suspended its 2025 outlook as medical costs ran higher than planned.
The Justice Department’s review of its Medicare billing also stayed unresolved, causing Wall Street players to abandon the stock.
Related: Morgan Stanley adjusts UNH stock price target after earnings
However, in the first quarter of 2026, UnitedHealth posted revenue of $111.7 billion and adjusted earnings of $7.23 a share, beating estimates and sending shares up more than 8%.
Its medical care ratio, the share of each premium dollar spent paying claims, improved to 83.9% from 84.8% a year earlier.
When that ratio falls, the insurer, UnitedHealth, keeps more of every premium dollar as profit, and the improvement to 83.9% rebuilt more confidence than any executive comment could.
What still has to go right for UNH stock
JPMorgan’s higher price target is a forecast, not a promise. Several things still need to go the right way.
The bullish case rests on these moving parts:
- The DOJ’s Medicare review needs to be resolved without forcing UnitedHealth to pay a heavy fine or return a large amount in past payments.
- UnitedHealth’s medical costs have to keep falling so that its care ratio maintains its recent improvement.
- Management must deliver on its pledge to return to long-term growth of 13% to 16%.
There is also a sentiment risk.
The stock has already run more than 20% in 2026, according to Stock Analysis data, so plenty of good news is already priced in.
Berkshire Hathaway, which bought UNH near $271 last year, exited the position entirely in the first quarter of 2026, according to 24/7 Wall St.
When an investor known for being patient sells a stock that quickly, it may signal that the easy money has already been made.
What this means if you own or are watching UNH
Wall Street has shifted from defense to offense on UnitedHealth, and the targets now sit comfortably above the current price.
For existing shareholders, a recovery thesis that looked fragile in January has found real support in earnings and analyst conviction.
If you’re considering a new position, you need to pay attention to timing.
UNH’s 20%-plus run already prices in much of the good news, and JPMorgan’s $466 target is only 14% away from current levels.
Related: JPMorgan doubles down on stock market message for 2026
